Cyndee Miranda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cyndee Miranda has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Zachary A. Yetmar
Department of Infectious Disease, Integrated Hospital-care Institute, Cleveland Clinic , Cleveland, Ohio
3 shared publications - Elena Beam
Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic , Rochester, Minnesota
2 shared publications J. Walton Tomford
Head, Section of Granulomatous Infections, Department of Infectious Disease, Medicine Institute, Cleveland Clinic
2 shared publications- Josh Clement
Department of Pharmacy, The Mount Sinai Hospital , New York, New York
2 shared publications - Nancy L. Wengenack
Department of Laboratory Medicine and Pathology, Mayo Clinic
2 shared publications - Paige K. Marty
Department of Pulmonary Medicine, Cleveland Clinic Foundation , Cleveland, Ohio
2 shared publications
Latest Publications
- Open Access
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Risk Factors and Outcomes of Disseminated Nocardiosis Across Host Risk Groups
Background: Nocardiosis primarily affects immunocompromised hosts and those with chronic pulmonary disease but can also occur in immunocompetent patients. Predictors of dissemination and its role in long-term mortality remain unclear. Methods: We conducted a retrospective cohort study of adults with nocardiosis diagnosed from January 1, 2010 to December 31, 2023. Patients were categorized into 3 groups: immunocompromised, immunocompetent with chronic lung disease, and immunocompetent without chronic lung disease. We evaluated risk factors associated with dissemination at the time of diagnosis and predictors of 1-year mortality. Multivariable logistic regression identified risk factors for dissemination. Cox regression assessed predictors of 1-year mortality. Results: Among 232 patients, 44 (19.0%) had disseminated infection and 36 (15.5%) died within 1-year. Dissemination was more common among patients who were immunocompromised (odds ratio ([OR] 6.26, 95% confidence interval [CI] 2.26–20.53) or immunocompetent without chronic lung disease (OR 5.09, 95% CI 1.75–17.15). Lymphopenia and infection with Nocardia farcinica were also independently associated with dissemination. Dissemination was not associated with mortality overall (hazard ratio [HR] 1.58, P = .222), though interaction analysis revealed that dissemination was significantly associated with 1-year mortality only in immunocompetent patients with chronic lung disease (HR 9.43, 95% CI 1.73–51.52). Conclusions: Immunocompromised patients and those without chronic lung disease are at increased risk for disseminated nocardiosis. While dissemination alone is not predictive of 1-year mortality overall, it is directly associated with mortality among immunocompetent patients with chronic lung disease. These findings highlight the need for tailored prognostic assessment and management in this subgroup.
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Open AccessRisk Factors and Outcomes of Disseminated Nocardiosis Across Host Risk Groups
Background: Nocardiosis primarily affects immunocompromised hosts and those with chronic pulmonary disease but can also occur in immunocompetent patients. Predictors of dissemination and its role in long-term mortality remain unclear. Methods: We conducted a retrospective cohort study of adults with nocardiosis diagnosed from January 1, 2010 to December 31, 2023. Patients were categorized into 3 groups: immunocompromised, immunocompetent with chronic lung disease, and immunocompetent without chronic lung disease. We evaluated risk factors associated with dissemination at the time of diagnosis and predictors of 1-year mortality. Multivariable logistic regression identified risk factors for dissemination. Cox regression assessed predictors of 1-year mortality. Results: Among 232 patients, 44 (19.0%) had disseminated infection and 36 (15.5%) died within 1-year. Dissemination was more common among patients who were immunocompromised (odds ratio ([OR] 6.26, 95% confidence interval [CI] 2.26–20.53) or immunocompetent without chronic lung disease (OR 5.09, 95% CI 1.75–17.15). Lymphopenia and infection with Nocardia farcinica were also independently associated with dissemination. Dissemination was not associated with mortality overall (hazard ratio [HR] 1.58, P = .222), though interaction analysis revealed that dissemination was significantly associated with 1-year mortality only in immunocompetent patients with chronic lung disease (HR 9.43, 95% CI 1.73–51.52). Conclusions: Immunocompromised patients and those without chronic lung disease are at increased risk for disseminated nocardiosis. While dissemination alone is not predictive of 1-year mortality overall, it is directly associated with mortality among immunocompetent patients with chronic lung disease. These findings highlight the need for tailored prognostic assessment and management in this subgroup.
- 15 April 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (4) , 701-702
Executive Summary of State-of-the-Art Review: Modern Approach to Nocardiosis—Diagnosis, Management, and Uncertainties
- 15 April 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (4) , 701-702
Executive Summary of State-of-the-Art Review: Modern Approach to Nocardiosis—Diagnosis, Management, and Uncertainties
- Top Cited Papers
- 15 April 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (4) , e53-e64
State-of-the-Art Review: Modern Approach to Nocardiosis—Diagnosis, Management, and Uncertainties
Nocardiosis is an uncommon yet potentially devastating infection. Nocardia tends to affect individuals with chronic lung disease or immunocompromising conditions, 2 groups increasing in number. Incidence of nocardiosis is likely to increase as well, and it is vital to have an approach to this complex disease. Here, we aim to review the presentation, diagnosis, and management of Nocardia in the modern era. We will also highlight areas of uncertainty in our understanding of nocardiosis and propose a general approach to nocardiosis therapy, accounting for response and tolerance of Nocardia treatment.
- 15 April 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (4) , e53-e64
Top Cited PapersState-of-the-Art Review: Modern Approach to Nocardiosis—Diagnosis, Management, and Uncertainties
Nocardiosis is an uncommon yet potentially devastating infection. Nocardia tends to affect individuals with chronic lung disease or immunocompromising conditions, 2 groups increasing in number. Incidence of nocardiosis is likely to increase as well, and it is vital to have an approach to this complex disease. Here, we aim to review the presentation, diagnosis, and management of Nocardia in the modern era. We will also highlight areas of uncertainty in our understanding of nocardiosis and propose a general approach to nocardiosis therapy, accounting for response and tolerance of Nocardia treatment.
- 17 March 2023
- Published by Springer Nature
- p. 21-38
Nontuberculous Mycobacterial Infections
- 1 January 2020
- Published by Elsevier in American Journal of Infection Control
- Vol. 48 (1) , 82-85
Addressing the threat from within: Investigation of respiratory symptoms in a health care worker with untreated latent tuberculosis infection
- 1 January 2020
- Published by Elsevier in American Journal of Infection Control
- Vol. 48 (1) , 82-85
Addressing the threat from within: Investigation of respiratory symptoms in a health care worker with untreated latent tuberculosis infection
- Open Access
- 1 September 2010
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 77 (9) , 606-611
Interferon-gamma-release assays: Better than tuberculin skin testing?
Although the tuberculin skin test has long been the standard for detecting latent tuberculosis infection, it has many limitations. Interferon-gamma-release assays are gaining acceptance as an alternative. In this paper we present cases to illustrate how these new tests can be used and how to interpret the results.
- 1 September 2010
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 77 (9) , 606-611
Open AccessInterferon-gamma-release assays: Better than tuberculin skin testing?
Although the tuberculin skin test has long been the standard for detecting latent tuberculosis infection, it has many limitations. Interferon-gamma-release assays are gaining acceptance as an alternative. In this paper we present cases to illustrate how these new tests can be used and how to interpret the results.
- 1 March 2009
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 30 (3) , 296-298
Reducing the Rates of Indeterminate Results of the QuantiFERON-TB Gold In-Tube Test During Routine Preemployment Screening for Latent Tuberculosis Infection Among Healthcare Personnel
Reducing the Rates of Indeterminate Results of the QuantiFERON-TB Gold In-Tube Test During Routine Preemployment Screening for Latent Tuberculosis Infection Among Healthcare Personnel - Volume 30 Issue 3 - Cyndee Miranda, Belinda Yen-Lieberman, Paul Terpeluk, J. Walton Tomford, Steven Gordon
- 1 March 2009
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 30 (3) , 296-298
Reducing the Rates of Indeterminate Results of the QuantiFERON-TB Gold In-Tube Test During Routine Preemployment Screening for Latent Tuberculosis Infection Among Healthcare Personnel
Reducing the Rates of Indeterminate Results of the QuantiFERON-TB Gold In-Tube Test During Routine Preemployment Screening for Latent Tuberculosis Infection Among Healthcare Personnel - Volume 30 Issue 3 - Cyndee Miranda, Belinda Yen-Lieberman, Paul Terpeluk, J. Walton Tomford, Steven Gordon